Reaction Details Report a problem with these data
Target
Galectin-3
Ligand
BDBM468295
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
1.000±n/a nM
Citation
 Leffler, H; Nilsson, U; Zetterberg, F Hybrid galactoside inhibitor of galectins US Patent  US10800804 Publication Date 10/13/2020 
Target
Name:
Galectin-3
Synonyms:
LEG3_HUMAN | LGALS3 | MAC2
Type:
Enzyme
Mol. Mass.:
26156.54
Organism:
Homo sapiens (Human)
Description:
P17931
Residue:
250
Sequence:
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI
  
Inhibitor
Name:
BDBM468295
Synonyms:
3,3′-Dideoxy-3,3′-di-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example SX
Type:
Small organic molecule
Emp. Form.:
C28H30F2N6O8S
Mol. Mass.:
648.635
SMILES:
OCC1O[C@@H](S[C@@H]2O[C@H](CO)C(O)C([C@H]2O)n2cc(nn2)-c2cccc(F)c2)C(O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1 |r|
Structure:
Search PDB for entries with ligand similarity: